Pam S Schwartz

Learn More
Cancer cells with elevated levels of BCL-2 and related survival proteins are broadly resistant to cytotoxic agents. Antisense oligodeoxynucleotides, and more recently small molecule ligands for BCL-2 and BCL-XL, are directly cytotoxic or synergistic with standard cytotoxic agents, and in some cases, may demonstrate selectivity for tumor cells. The usual(More)
Cancer cells with elevated levels of Bcl-2 and the related anti-apoptotic proteins Bcl-x(L), Mcl-1 and Bcl-W are broadly resistant to standard anticancer drugs and other therapeutic modalities. Antisense oligodeoxynucleotides and, more recently, small-molecule ligands for Bcl-2 and Bcl-x(L), sensitize cancer cells to cytotoxic therapies. In some cases,(More)
Bcl-2, the first regulator of core apoptotic pathways to be identified, was discovered as an oncogene in follicular lymphoma by Stan Korsmeyer, Carlo Croce and Mike Cleary. The subsequent discovery in the Korsmeyer lab of Bax, a Bcl-2 homologue with proapoptotic effects, as a binding partner of Bcl-2, led to the rheostat model of opposing Bcl-2 and Bax(More)
The Food and Drug Administration's (FDA) current research programme on migration from food packaging materials focuses on high-temperature packaging applications. Results from two studies conducted by Arthur D. Little, Inc., under contract to the FDA, are presented as well as highlights of the FDA's research programme on migration from microwave heat(More)
  • 1